Evidence map›Paper›PMID 39516711›Full record

ArticleScientific reports2024

Assessing the diagnostic utility of urinary albumin-to-creatinine ratio as a potential biomarker for diabetic peripheral neuropathy in type 2 diabetes mellitus patients.

Hui Zhang, Shufang Yang, Hongxiao Wang, Huzaifa Fareeduddin Mohammmed Farooqui, Wenwen Zhu, Tong Niu, Zhen Zhang, Yang Chen, Ling Huang, Ya Zhang and 4 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hui Zhang *Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
Shufang Yang *Department of Endocrinology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China.
Hongxiao Wang *Department of Endocrinology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
Huzaifa Fareeduddin Mohammmed FarooquiDepartment of Endocrinology, Affiliated Zhongda Hospital of Southeast University, Nanjing, China.
Wenwen ZhuDepartment of Endocrinology, Affiliated Zhongda Hospital of Southeast University, Nanjing, China.
Tong NiuDepartment of Endocrinology, Affiliated Zhongda Hospital of Southeast University, Nanjing, China.
Zhen ZhangDepartment of Endocrinology, Institute of Endocrine and Metabolic Diseases, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Yang ChenDepartment of Endocrinology, Institute of Endocrine and Metabolic Diseases, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Ling HuangDepartment of Endocrinology, Institute of Endocrine and Metabolic Diseases, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Ya ZhangDepartment of Endocrinology, Institute of Endocrine and Metabolic Diseases, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Mengting HeDepartment of Endocrinology, Institute of Endocrine and Metabolic Diseases, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Bing SongDepartment of Endocrinology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China. songbing1978@163.com.
Songtao FengDepartment of Nephrology, Jiangsu University Affiliated People's Hospital, Zhenjiang, China. fengsongtao@126.com.
Haoqiang ZhangDepartment of Endocrinology, Institute of Endocrine and Metabolic Diseases, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China. drhqzhang@ustc.edu.cn.

Funding

China Endocrine Metabolism Talent Research Project from China International Medical Foundation 2023-N-03-12Research Funds of Center for Leading Medicine and Advanced Technologies of IHM 2023IHM02006Scientific Research Start-up Funds of The First Affiliated Hospital of USTC RC2021178Taizhou People's Hospital Hospital-level Scientific Research Fund Project ZL202219Zhenjiang Jinshan Talent Medical High Level Talent Project JSYC2023-11
6 · The paper itself

Abstract

BACKGROUND AND

aimsDiabetic peripheral neuropathy (DPN) and diabetic nephropathy (DN) both have microcirculation dysfunction. Urinary albumin-to-creatinine ratio (UACR) is a biomarker for DN. We aimed to explore the links between DPN and UACR in patients with type 2 diabetes mellitus (T2DM).

methodsA total of 195 T2DM patients were defined as Control or DPN group. Clinical parameters were compared, and the association between HbA1c (or UACR) and DPN was analyzed. Risk factors for DPN were observed, and the diagnostic values of HbA1c and UACR were assessed.

resultsCompared with 104 participants without DPN, 91 individuals with DPN exhibited higher HbA1c and UACR levels. In all patients, increased HbA1c and UACR were identified as risk factors for DPN in individuals with T2DM. Moreover, increased HbA1c was a risk factor for DPN in volunteers without DN, whereas elevated UACR was determined as a risk factor for DPN in participants with DN. The cut-off point for HbA1c (7.65%) in patients without DN had a sensitivity of 86.0% and specificity of 44.6%, while the cut-off point for UACR (196.081 mg/g) in patients with DN had a sensitivity of 52.9% and specificity of 76.2%.

conclusionElevated HbA1c and UACR levels are risk factors for DPN and may serve as potential biomarkers for DPN in T2DM patients.

Indexed as

AlbuminuriaBiomarkersCreatinineDiabetes Mellitus, Type 2Diabetic NeuropathiesGlycated HemoglobinAgedDiabetic NephropathiesFemaleHumansMaleMiddle AgedRisk FactorsBiomarkersCreatinineGlycated Hemoglobinhemoglobin A1c protein, humanDiabetic peripheral neuropathyType 2 diabetes mellitusUrinary albumin-to-creatinine ratio

Identifiers

PMID39516711
PMCPMC11549456

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.